Image

Lupus Nephritis

Uncover what other tests can’t see with AVISE® SLE Monitor, the most advanced autoimmune testing available.

Know more with
AVISE® SLE Monitor

The most advanced assessment available

With a powerful combination of biomarkers that go beyond standard SLE tests, AVISE® SLE Monitor empowers you with the full intel to stay a step ahead of flare ups, regularly monitor disease progression, assess treatment efficacy, and help prevent premature disease advancement and long-term damage.

Image

A more advanced assessment requires a more comprehensive biomarker suite


AVISE SLE Monitor

Organ involvement

Anti-C1q

Disease Activity

Soluble C3/C4
Anti-dsDNA by CIA
EC4d Powered by CB-CAPs

Optional Add-Ons

Therapeutic drug monitoring

HCQ
MTX

EC4d is informative even when C3/C4 is unchanged

In a cohort of 124 SLE patients that were followed longitudinally, levels of EC4d fluctuated with disease activity and provided additional information regardless of changes in C3/C4 levels.1

22%

Fluctuating C3/C4 Levels

78% EC4d disease correlation independent of C3/C4 levels in this patient group

Chronic Levels

Marginal R2 =7.9% (p <0.001)

ES4d is informative even when C3/C4 is unchanged

In a cohort of 124 SLE patients that were followed longitudinally, levels of EC4d fluctuated with disease activity and provided additional information regardless of changes in C3/C4 levels.

22%

Fluctuating C3/C4 Levels

78% EC4d disease correlation independent of C3/C4 levels in this patient group

Chronic Low or Normal C3/C4 Levels

Marginal R2 =7.9% (p <0.001)

Image

Superior detection of organ involvement


Anti-C1q: Identify the risk of Lupus Nephritis

Anti-C1q is superior to other biomarkers in association with SELENA-SLEDAI values and lupus nephritis. SLE patients with positive levels are 2X more likely to have renal involvement.3

Image
Percent of patients with increased biomarker levels during high disease activity3

Superior detection of changes in disease activity


EC4d: More accurate monitoring

Our proprietary CB-CAPs EC4d test has strong correlation with disease activity and levels decline rapidly with clinical improvement.4


EC4d & Disease Activity

Anti-dsDNA by CIA: Superior accuracy

Chemiluminescence immunoassay (CIA) has expanded dynamic range and demonstrated superior agreement with the Farr assay.1


Anti-dsDNA & Disease Activity

Superior detection of Lupus Nephritis


EC4d & Lupus Nephritis Activity
Anti-C1q & Lupus Nephritis Activity
EC4d and anti-C1q significantly correlate with decreases in proteinuria observed prospectively—importantly, EC4d had a stronger correlation with uPCR than conventional serum C3/C4.4
Anti-C1q antibodies are significantly associated (OR = 3.2, p < 0.01) with LN independent of demographic and other serological risk factors.1,2
SLE patients who are simultaneously anti-dsDNA, low complement, and anti-C1q positive are most strongly associated (OR = 14.9, p < 0.01) with LN.2

You deserve quality test results you can trust.

Take control over your patient’s lupus with regular monitoring. Uncover what other tests can’t see with AVISE® SLE Monitor, the most advanced autoimmune testing available.

AVISE SLE Monitor is a specialized SLE Disease Monitoring Test Clinically Proven To Correlate With SLE Disease Activity.

The AVISE SLE Monitor test should be considered any time the condition of a SLE patient is being assessed.

Order your AVISE Testing Starter Kit today!

Clinical Utility: AVISE SLE Monitor Test Report

The AVISE SLE Monitor test should be considered any time the condition of a SLE patient is being assessed.

If the patient is also being monitored with AVISE® HCQ, the AVISE SLE Monitor test report will also include an AVISE HCQ test result page.